

To the editor:

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Peter L. Greenberg,¹ Heinz Tuechler,² Julie Schanz,³ Guillermo Sanz,⁴ Guillermo Garcia-Manero,⁵ Francesc Solé,⁶ John M. Bennett,⁷ David Bowen,⁸ Pierre Fenaux,⁹ Francois Dreyfus,¹⁰ Hagop Kantarjian,⁵ Andrea Kuendgen,¹¹ Alessandro Levis,¹² Luca Malcovati,¹³ Mario Cazzola,¹³ Jaroslav Cermak,¹⁴ Christa Fonatsch,¹⁵ Michelle M. Le Beau,¹⁶ Marilyn L. Slovak,¹⁷ Otto Krieger,¹⁸ Michael Luebbert,¹⁹ Jaroslaw Maciejewski,²⁰ Silvia M. M. Magalhaes,²¹ Yasushi Miyazaki,²² Michael Pfeilstöcker,² Mikkael Sekeres,²⁰ Wolfgang R. Sperr,¹⁵ Reinhard Stauder,²³ Sudhir Tauro,²⁴ Peter Valent,¹⁵ Teresa Vallespi,²⁵ Arjan A. van de Loosdrecht,²⁶ Ulrich Germing,¹¹ and Detlef Haase³

¹Stanford University Cancer Institute, Stanford, CA; ²Hanusch Hospital, Boltzmann Institute for Leukemia Research, Vienna, Austria; ³Georg August Universität, Göttingen, Germany; ⁴Hospital Universitario La Fe, Valencia, Spain; ⁵University of Texas, MD Anderson Cancer Center, Houston, TX; ⁶Hospital del Mar, Barcelona, Spain; ⁷University of Rochester Medical Center, James P. Wilmot Cancer Center, Rochester, NY; ⁸St. James's University Hospital, Leeds, United Kingdom; ⁹Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP)/University Paris XIII, Bobigny, France; ¹⁰Hôpital Cochin, AP-HP/University Paris V, Paris, France; ¹¹Heinrich-Heine University Hospital, Düsseldorf, Germany; ¹²Antonio e Biagio e C Arrigo Hospital, Alessandria, Italy; ¹³Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy; ¹⁴Institute of Hematology and Blood Transfusion, Praha, Czech Republic; ¹⁵Medical University of Vienna, Vienna, Austria; ¹⁶The University of Chicago Comprehensive Cancer Research Center, Chicago, IL; ¹⁷Quest Diagnostics Nichols Institute, Chantilly, VA; ¹⁸Elisabethinen Hospital, Linz, Austria; ¹⁹University of Freiburg Medical Center, Freiburg, Germany; ²⁰Cleveland Clinic, Cleveland, OH; ²¹Federal University of Ceara, Fortaleza, Brazil; ²²Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; ²³University Hospital of Innsbruck, Innsbruck, Austria; ²⁴University of Dundee, Scotland, United Kingdom; ²⁵Hospital Universitario Vall d'Hebron, Barcelona, Spain; and ²⁶VU University Medical Center, Amsterdam, The Netherlands

The recent article by Arber et al¹ detailing the 2016 revision of the World Health Organization (WHO) classification of myeloid malignancies and AML was timely and germane. Regarding myelodysplastic syndromes (MDS), the authors indicate diagnostic criteria that include levels of dysplasia and cytopenias. They further indicated that ethnic variation should be taken into consideration in patients with borderline low neutrophil counts and that a diagnosis of MDS may still be made in “rare cases with milder levels of cytopenia” when definitive morphologic and/or cytogenetic features are present.^{1,2} The necessity of clarifying these criteria has major relevance, particularly with the advent of a recently described group of indolent hematopoietic disorders that may represent precursor states of MDS such as idiopathic cytopenia of unknown significance (ICUS),³⁻⁵ idiopathic dysplasia of unknown significance (IDUS),^{5,6} clonal hematopoiesis of unknown potential (CHIP),⁷ and clonal cytopenia of unknown significance (CCUS)^{4,8,9} that require distinction from MDS. It is recognized that ICUS is not necessarily myeloid (unrecognized lymphoid or plasma cell neoplasms may cause idiopathic cytopenias that may be classified

initially as ICUS, and some patients with ICUS may eventuate into nonhematopoietic/reactive disorders such as immune dysregulation), whereas IDUS is a morphological alteration with many potential causes that do not necessarily influence hematopoiesis in terms of the number of generated cells. These entities have been reviewed in the current National Comprehensive Cancer Network MDS Practice Guidelines 1.2017.¹⁰

However, although the WHO perspective indicates that “cytopenia is a sine qua non for any MDS diagnosis,”¹¹ the recommended threshold levels of cytopenias it proposes for this purpose are those previously reported in the International Prognostic Scoring System (IPSS) risk stratification categorization that were used for *prognostic but not diagnostic* purposes (hemoglobin [Hb] 10 g/dL, absolute neutrophil count [ANC] $1.8 \times 10^9/L$, platelets $100 \times 10^9/L$).¹¹ Table 1 provides data from the International Working Group for Prognosis in MDS (IWG-PM) database that was used to generate the Revised-IPSS¹²; if these cytopenia levels were used to diagnose MDS, 18% of MDS patients and 23% of those with <5% marrow blasts would lack any

Table 1. Cytopenias in MDS

Marrow blasts	Cytopenias								Total
	None, n	None, %	1, n	1, %	2, n	2, %	3, n	3, %	
Less than normal*									
<5%	106	2.3	1946	43	1543	34	950	21	4545
≥5%	19	0.8	421	17	927	38	1100	45	2467
Total	125	1.8	2367	34	2470	35	2050	29	7012
Less than normal, without CMML*									
<5%	73	1.7	1814	43	1395	33	912	22	4194
≥5%	8	0.4	318	15	792	37	1047	48	2165
Total	81	1.3	2132	34	2187	34	1959	31	6359
WHO categorization†									
<5%	1040	23	1988	44	1064	23	453	10	4545
≥5%	197	8	776	32	922	37	572	23	2467
Total	1237	18	2764	39	1986	28	1025	15	7012

Percent values rounded off except for values <3%. Data obtained from Greenberg et al.¹²

CMML, chronic myelomonocytic leukemia.

*Standard values: Hb <13 g/dL (males), <12 g/dL (females), ANC < $1.8 \times 10^9/L$, platelets < $150 \times 10^9/L$.

†IPSS values: Hb <10 g/dL, ANC < $1.8 \times 10^9/L$, platelets < $100 \times 10^9/L$.

cytopenia and thus would not be classifiable as MDS. Using standard laboratory values for cytopenias (Hb <13 g/dL [males], <12 g/dL [females], ANC <1.8 × 10⁹/L, platelets <150 × 10⁹/L), the data demonstrated that only 1.8% patients evaluated in that study of 7012 MDS subjects would lack a cytopenia (1.3% of patients when nonproliferative chronic myelomonocytic leukemia patients were excluded). Of note, and relevant predominantly for patients with low marrow blast counts in the IWG-PM cohort, the patient's blood counts also needed to demonstrate ≥2 months of stable disease as a potential means of excluding other causes for the cytopenias.

Regarding our main point, it is of relevance that the MDS database (n = 816) used to generate the IPSS (Table 1)¹¹ similarly demonstrated that 19% of these patients lacked a cytopenia if defined by the prognostic level cutpoints used by the WHO and also incorrectly would not have been considered to have MDS. Similar findings were found in an independent study using these cytopenic cutpoints.¹³ Prior investigations have demonstrated ethnic-, age-, and altitude-related differences in normal Hb levels^{14,15}; ethnic-, age-, and sex-related differences in platelet levels^{16,17}; and ethnic- and sex-related differences in platelet and white counts.¹⁸ Thus, being cognizant of these conditional blood count variations, we recommend that standard hematologic values be used to define cytopenias in MDS and believe a modification of the WHO definition of cytopenias as 1 of the criteria (in addition to definitive morphologic and/or cytogenetic findings) to diagnose MDS would be valuable and most accurate.

Contribution: P.L.G. and H.T. designed the study, analyzed the data, and wrote the report; A.A.v.d.L., D.H., J.M.B., P.F., M.C., and U.G. critically reviewed and modified the manuscript and contributed data to the IWG-PM database; and the remaining authors contributed data to the IWG-PM database and critically reviewed and approved the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Peter L. Greenberg, Stanford University Cancer Institute, 875 Blake Wilbur Dr #2335, Stanford, CA 94305-5821; e-mail: peterg@stanford.edu.

References

- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20):2391-2405.
- Bruning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms. In: Swerdlow S, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC Press; 2008:88.
- Wimazal F, Fonatsch C, Thalhammer R, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. *Leuk Res*. 2007;31(11):1461-1468.
- Kwok B, Hall JM, Witte JS, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. *Blood*. 2015;126(21):2355-2361.
- Valent P, Bain BJ, Bennett JM, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. *Leuk Res*. 2012;36(1):1-5.
- Valent P, Jäger E, Mitterbauer-Hohendanner G, et al. Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. *Am J Cancer Res*. 2011;1(4):531-541.
- Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood*. 2015;126(1):9-16.
- McKerrell T, Park N, Moreno T, et al; Understanding Society Scientific Group. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. *Cell Reports*. 2015;10(8):1239-1245.
- Cargo CA, Rowbotham N, Evans PA, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. *Blood*. 2015;126(21):2362-2365.
- Greenberg PL, Stone R, Bejar R, et al., eds. NCCN Practice Guidelines for Myelodysplastic Syndromes, version 1. 2017. (www.nccn.org/professionals/physician_gls/PDF/mds.pdf).
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood*. 1997;89(6):2079-2088.
- Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*. 2012;120(12):2454-2465.
- Germing U, Strupp C, Kuendgen A, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. *Haematologica*. 2006;91(12):1596-1604.
- Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? *Blood*. 2006;107(5):1747-1750.
- Beutler E. Hemoglobin levels, altitude, and smoking. *Blood*. 2006;108(6):2131-2132.
- Segal JB, Moliterno AR. Platelet counts differ by sex, ethnicity, and age in the United States. *Ann Epidemiol*. 2006;16(2):123-130.
- Biino G, Santimone I, Minelli C, et al. Age- and sex-related variations in platelet count in Italy: a proposal of reference ranges based on 40987 subjects' data. *PLoS One*. 2013;8(1):e54289.
- Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. *J Clin Pathol*. 1996;49(8):664-666.

DOI 10.1182/blood-2016-07-728766

© 2016 by The American Society of Hematology

To the editor:

Chronic neutrophilic leukemia in a child with a *CSF3R* T618I germ line mutation

Lawrence J. Druhan,¹ Daniel P. McMahon,² Nury Steuerwald,¹ Andrea E. Price,¹ Amanda Lance,¹ Jonathan M. Gerber,¹ and Belinda R. Avalos¹

¹Department of Hematologic Oncology and Blood Disorders, The Levine Cancer Institute, and ²Pediatric Hematology/Oncology, The Levine Children's Hospital, Carolinas HealthCare System, Charlotte, NC

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm characterized by sustained elevation of neutrophil count, splenomegaly, and poor prognosis. Activating mutations in the colony-stimulating factor 3 receptor (*CSF3R*), also known as the granulocyte colony-stimulating factor (G-CSF) receptor, have recently been identified in 80% of patients studied with CNL.^{1,2} The most common

mutation is T618I, which renders the receptor ligand independent through constitutive JAK/STAT activation.^{1,3} The strong association of activating *CSF3R* mutations with CNL has led to the addition of a *CSF3R* T618I mutation or other activating *CSF3R* mutation to the diagnostic criteria for CNL in the 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia.⁴